Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML

JHOP - August 2023 Vol 13, No 4 - FDA Oncology Update
NEW DRUGS

On July 20, 2023, the FDA approved quizartinib (Vanflyta; Daiichi Sankyo) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)–positive, as detected by an FDA-approved test.

Quizartinib is an orally administered small-molecule inhibitor of the tyrosine kinase receptor FLT3.

The efficacy of quizartinib plus chemotherapy was evaluated in QuANTUM-First (NCT02668653), a randomized, double-blind, placebo-controlled trial of 539 patients with newly diagnosed FLT3-ITD–positive AML. FLT3-ITD status was determined prospectively with a clinical trial assay and verified retrospectively with the companion diagnostic LeukoStrat CDx FLT3 Mutation Assay.

In the study, patients were randomized to receive quizartinib (n=268) or placebo (n=271) with induction and consolidation therapy and as maintenance monotherapy according to the initial assignment. Efficacy was established on the basis of overall survival (OS), which was measured from the date of randomization until death by any cause. The primary analysis was conducted after a follow-up of ≥24 months after the randomization of the last patient. The study demonstrated a significant improvement in OS in the quizartinib arm (hazard ratio, 0.78; 95% confidence interval, 0.62-0.98; 2-sided P=.0324).

Quizartinib is not indicated as maintenance monotherapy in patients who received allogeneic hematopoietic stem cell transplantation; improvement in OS with quizartinib in this setting has not been demonstrated.

Quizartinib is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) program called Vanflyta REMS because of the serious risk for QT prolongation, torsades de pointes, and cardiac arrest. A boxed warning is included in the prescribing information for quizartinib.

The requirements of the Vanflyta REMS program include:

  • Prescribers must be certified in the Vanflyta REMS program by enrolling and completing training.
  • Prescribers must counsel patients receiving quizartinib about the risk for QT prolongation, torsades de pointes, and cardiac arrest, and provide patients with a patient wallet card.
  • Pharmacies that dispense quizartinib must be certified with the Vanflyta REMS program and must verify that prescribers are certified through Vanflyta REMS.

A treatment course of quizartinib consists of ≤2 cycles of quizartinib in combination with induction cytarabine and anthracycline, ≤4 cycles of quizartinib in combination with high-dose cytarabine consolidation, and ≤36 cycles of quizartinib as maintenance therapy or until disease progression or unacceptable adverse events. Quizartinib maintenance therapy should be initiated after consolidation chemotherapy once the absolute neutrophil count is >500/mm3 and the platelet count is >50,000/mm3.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: